Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

ebewe pharma ges. m.b.h. nfg. kg - oxaliplatin - concentrate for solution for infusion - 5mg/ml

Malta - English - Malta Medicines Authority

ebewe pharma gmbh nfg. kg mondseestrasse 11, 4866 unterach, austria - gemcitabine - concentrate for solution for infusion - gemcitabine - antineoplastic agents

Malta - English - Malta Medicines Authority

ebewe pharma gmbh nfg. kg mondseestrasse 11, 4866 unterach, austria - oxaliplatin - concentrate for solution for infusion - oxaliplatin 5 mg/ml - antineoplastic agents

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

ebewe pharma ges. m.b.h. nfg. kg - cisplatin - concentrate for solution for infusion - 0,5mg/ml

Malta - English - Malta Medicines Authority

ebewe pharma gmbh nfg. kg - oxaliplatin 5 mg/ml - powder for solution for infusion

United States - English - NLM (National Library of Medicine)

ebewe pharma ges.m.b.h. nfg.kg - fulvestrant (unii: 22x328qoc4) (fulvestrant - unii:22x328qoc4) - monotherapy fulvestrant injection is indicated for the treatment of: fulvestrant injection is indicated for the treatment of: fulvestrant is contraindicated in patients with a known hypersensitivity to the drug or to any of its components. hypersensitivity reactions, including urticaria and angioedema, have been reported in association with fulvestrant [seeadverse reactions (6.2) ]. risk summary based on findings from animal studies and its mechanism of action, fulvestrant can cause fetal harm when administered to a pregnant woman [seeclinical pharmacology (12.1)]. there are no available data in pregnant women to inform the drug-associated risk. in animal reproduction studies, administration of fulvestrant to pregnant rats and rabbits during organogenesis caused embryo-fetal toxicity, including skeletal malformations and fetal loss, at daily doses that were 6% and 30% of the maximum recommended human dose based on mg/m2 , respectively [see data ]. advise pregnant women of the potential risk to a fetus. the e

Israel - English - Ministry of Health

novartis israel ltd - methotrexate - solution for injection - methotrexate 20 mg/ml - methotrexate - methotrexate - psoriasis: methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well established according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease- modifying antirheumatic drugs.juvenile idiopathic arthritis:treatment of polyarthritic forms of severe, active juvenile idiopathic arthritis in patients 3 years of age and above when the response to non-steroidal anti-inflammatory drugs (nsaids) has been inadequatecrohn’s disease: mild to moderate crohn's disease either alone or in combination with corticosteroids in adult patients ref

Israel - English - Ministry of Health

novartis israel ltd - mitoxantrone as hydrochloride - concentrate for solution for infusion - mitoxantrone as hydrochloride 2 mg/ml - mitoxantrone - mitoxantrone - treatment of advanced breast cancer, non-hodgkin's lymphomas, acute non lymphocytic leukemia palliation of non resectable primary hepatocellular carcinoma. mitoxantrone in combination with corticosterolds is indicated for inital chemotherapy in patients with pain due to advanced hormone-refractory prostate cancer. for reduction of neurologic disability and/or frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remmitting multiple sclerosis (patients whose neurologic status is significantly abnormal between relapses), for patients 18-55 years old.בקשה לשינוי התוויה: 5/1/2021mitoxantrone is indicated in the treatment of metastatic breast cancer.mitoxantrone is indicated in the treatment of non-hodgkin’s lymphoma.mitoxantrone is indicated for the treatment of acute myeloid leukaemia (aml) in adults.mitoxantrone in combination regimens is indicated in the remission-induction treatment of blast crisis in chronic myeloid leukaemia.mitoxantrone is indicated in combination with corticosteroids for palliation (e.g. pain relief) related to advanced castrate resistant prostate cancer.mitoxantrone is indicated for treatment of patients with highly active relapsing multiple sclerosis associated with rapidly evolving disability where no alternative therapeutic options exist.

Malta - English - Malta Medicines Authority

ebewe pharma gmbh nfg. kg mondseestrasse 11, 4866 unterach, austria - gemcitabine - concentrate for solution for infusion - gemcitabine - antineoplastic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

ebewe pharma ges.m.b.h nfg. kg - paclitaxel - concentrate for soln for inf - 6 mg/ml